Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with cervical cancer who are older than 18 years of age.
• People who are willing and able to sign a consent form before taking part in any study-related procedures.
• People who are able to attend scheduled visits, follow treatment schedules, complete lab and imaging tests, and fill out quality of life questionnaires.
• People whose cervical cancer has been confirmed by a tissue sample (biopsy) and is at a specific stage (IB3 to IIIC1).
• People whose cancer is one of these types: squamous cell, adenosquamous, or adenocarcinoma.
• People who have not had any prior treatment for cervical cancer.
• People whose cancer can be measured by CT scan, MRI, or PET/CT scan, with that measurement taken within 28 days before joining the trial.
• People with a general health and activity level rated 0–2 on the WHO scale (confirm with trial site).
• People with a Charlson Comorbidity Index score of 1–4, which is a score used by doctors to measure the overall burden of other health conditions (confirm with trial site).
• People who are considered suitable to receive the chemotherapy drug cisplatin.
• People whose blood, kidney, and liver function results fall within acceptable ranges as measured by specific blood tests (confirm with trial site for exact values).
• People whose chest scan shows no signs of cancer that has spread or serious infections.
• People who have a negative pregnancy test (for those who could become pregnant).
• People who are not already enrolled in another clinical trial at the same institution.

Who may not be able to join:

• People whose cervical cancer is a rare type, such as small-cell carcinoma, glassy cell carcinoma, melanoma, sarcoma, or lymphoma.
• People whose cancer cannot be measured by imaging scans.
• People who are found to be pregnant during the enrolment process.
• People whose cancer is at a more advanced stage (IIIC2 to IVB).
• People who have serious infections or conditions such as hepatitis or HIV that could be made worse by chemotherapy or that would limit its use.
• People who already have nerve damage (neuropathy) of any kind before joining the trial.
• People who are currently taking part in another experimental drug study.
• People with certain mental health conditions, including severe major depression (with or without psychotic symptoms), schizophrenia, bipolar-type schizoaffective disorder, intellectual disabilities, autism, eating disorders, or a combination of a psychiatric diagnosis and recreational substance use — or those attending the consultation under coercion (confirm with trial site for full details).
• People with severe obesity, defined as a body mass index (BMI) over 40 kg/m², due to increased risks and difficulties associated with certain treatments.
• People who miss five consecutive follow-up appointments during the study.
• People who have previously had a full or partial hysterectomy (surgical removal of the uterus).
• People who have previously received chemotherapy or other anti-cancer drugs for cervical cancer other than cisplatin at a specific dose (40 mg/m²).
• People who have previously used or plan to use the drug Bevacizumab, either for another condition or as part of cervical cancer treatment.
• People with a Charlson Comorbidity Index score above 5.
• People who have another active cancer at the same time, except for non-melanoma skin cancer.
• People who have previously received radiation therapy to the pelvic area for another cancer.
• People with inflammatory bowel disease or connective tissue (collagen) diseases.
• People with severely weakened immune systems, such as those who have had an organ transplant or are taking immunosuppressive medications.
• People who do not sign the informed consent form.
• People with suspected alcohol or recreational drug misuse.
• People who have participated in another clinical trial within the 90 days before joining this study.
• People with any other illness or disability that, in the researchers' judgment, could put their safety or ability to follow the study at risk.
• People whose rectal radiation dose exceeds a specific technical threshold used in radiotherapy planning (confirm with trial site for details).

Important: Always verify eligibility with the trial site directly before applying.